Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
Coalition of Blood for Africa (CoBA) has shared a post on LinkedIn:
“Blood shortages
30-day expiry limits
Type matching chaos
Japan may have just solved all three.
At Nara Medical University, researchers are engineering a breakthrough in transfusion medicine — artificial blood that:
Doesn’t require blood type matching
Lasts up to 2 years (vs. 30 days for regular donations)
Is… purple
How?
Professor Hiromi Sakai and her team have developed a synthetic blood substitute by extracting hemoglobin from expired blood donations and encapsulating it in a virus-proof shell.
No blood type compatibility issues
Converts medical waste into lifesaving supply
Ideal for trauma, surgery, and remote care
Clinical trials are already underway, with human participants receiving 100–400ml doses. If successful, Japan aims for nationwide use by 2030.
Meanwhile, Professor Teruyuki Komatsu at Chuo University is developing artificial oxygen carriers using albumin (a plasma protein) — targeting use in stroke treatment, haemorrhage, and acute pressure crashes.
Why this matters
Global blood supply is often fragile — especially during disasters, pandemics, and in low-resource settings.
Artificial blood could extend shelf life 24x longer than current donations.
Eliminating type-matching delays could revolutionize emergency care.
This is not just scientific progress, it could be the most significant advance in transfusion medicine in decades, with massive implications for maternal health, surgery, battlefield medicine, and disaster response.
The future of blood may not be red.
It may be purple — and always ready when we need it most.”
Discover more on Hemostasis Today.
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 2, 2025, 14:14Nihar Desai: Post-Transplant Dysphagia
-
Nov 2, 2025, 14:13Zia Choudhry Launchs a New Digital Education Platform Designed to Inform and Empower People Living With wAIHA
-
Nov 2, 2025, 14:13Rahul Bhargava: Landmark Study Shows Excellent Outcomes in Pediatric AML Transplant
-
Nov 2, 2025, 10:17ESO: Register for the Live WSC 2025 Highlights Webinar
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Nov 2, 2025, 14:15Raul Santos: Waist-to-Height Ratio and Coronary Artery Calcium Incidence
-
Nov 2, 2025, 14:12Steven AR Murphy: Urolithin A Shows Immune Rejuvenation and Mitochondrial Benefits in New Trial
-
Nov 2, 2025, 10:31Cihan Ay and RIETE Investigators Team Present External Validation of the VTE-PREDICT Score
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry
-
Nov 2, 2025, 10:03Mark Stoffels: A Stroke Can Change Lives in an Instant, But With Timely Expert Care Recovery is Possible
-
Nov 2, 2025, 09:43Louise Bannon Celebrates Barbara Adams Krolak’s 10-Year Anniversary at ISTH
-
Nov 2, 2025, 08:06Sanam Loghavi Recognized at Inaugural Women in Hematology U.S. Focus Meeting 2025